MCID: UTR033
MIFTS: 49

Uterine Corpus Cancer malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Cancer

Aliases & Descriptions for Uterine Corpus Cancer:

Name: Uterine Corpus Cancer 12 14 69
Malignant Uterine Corpus Neoplasm 69
Corpus Uteri Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9460
ICD10 33 C54 C54.9
ICD9CM 35 182
NCIt 47 C3556
UMLS 69 C0153574

Summaries for Uterine Corpus Cancer

Disease Ontology : 12 A uterine cancer that is located in the uterine corpus.

MalaCards based summary : Uterine Corpus Cancer, also known as malignant uterine corpus neoplasm, is related to endometrial cancer and uterine corpus endometrial carcinoma. An important gene associated with Uterine Corpus Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Gene Expression and Deubiquitination. The drugs Progesterone and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include lymph node, breast and bone, and related phenotypes are Increased cell death HMECs cells and cellular

Related Diseases for Uterine Corpus Cancer

Diseases related to Uterine Corpus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 149)
id Related Disease Score Top Affiliating Genes
1 endometrial cancer 11.0
2 uterine corpus endometrial carcinoma 11.0
3 uterine body mixed cancer 11.0
4 uterine corpus sarcoma 11.0
5 uterine corpus serous adenocarcinoma 11.0
6 cystinosis, nephropathic 10.3 ERBB2 TP53
7 aortitis 10.3 PGR TP53
8 mouth disease 10.3 ERBB2 PGR
9 bone giant cell tumor 10.3 ERBB2 MYC
10 pericardium leiomyoma 10.3 PGR TP53
11 mucoepidermoid thyroid carcinoma 10.3 ERBB2 PGR
12 adult central nervous system mature teratoma 10.3 ERBB2 TP53
13 triple-receptor negative breast cancer 10.3 ERBB2 PGR
14 breast ductal carcinoma 10.3 PGR TP53
15 skin sarcoma 10.3 ERBB2 PGR
16 acinar cell carcinoma 10.3 PGR TP53
17 classic congenital mesoblastic nephroma 10.2 PGR TP53
18 kunjin encephalitis 10.2 BRCA1 ERBB2
19 porokeratosis 10.2 PGR TP53
20 central nervous system tuberculosis 10.2 FBXW7 PGR
21 autoimmune disease of cardiovascular system 10.2 BRCA1 PGR
22 heart malignant hemangiopericytoma 10.2 BRCA1 PGR
23 oro-mandibular-limb hypogenesis syndrome 10.2 ERBB2 TP53
24 mood disorder 10.2 KIT MYC
25 basaloid squamous cell carcinoma 10.2 ERBB2 PGR
26 infiltrating angiolipoma 10.2 ERBB2 PGR
27 reticulosarcoma 10.2 SMUG1 TP53
28 pulmonary artery choriocarcinoma 10.2 ERBB2 SMUG1
29 choriocarcinoma of ovary 10.2 KIT TP53
30 marfanoid hypermobility syndrome 10.2 KIT PGR
31 novak syndrome 10.2 ERBB2 SMUG1
32 barnicoat baraitser syndrome 10.2 MYC TP53
33 sclerosing breast papilloma 10.1 SMUG1 TP53
34 lung clear cell-sugar-tumor 10.1 BRCA1 ERBB2 TP53
35 bladder colloid adenocarcinoma 10.1 BRCA1 ERBB2 TP53
36 placenta praevia 10.1 ERBB2 MYC TP53
37 liver angiosarcoma 10.1 KIT PGR
38 uterine hypoplasia 10.1 KIT PGR
39 glucose-6-phosphate translocase deficiency 10.1 ERBB2 MYC TP53
40 breast pericanalicular fibroadenoma 10.1 BRCA1 PGR TP53
41 mediastinum leiomyosarcoma 10.1 PGR SMUG1
42 bladder clear cell adenocarcinoma 10.1 ESR1 TP53
43 seminoma 10.1 PGR TP53
44 human granulocytic anaplasmosis 10.1 KIT MYC TP53
45 ovarian embryonal carcinoma 10.1 KIT PGR TP53
46 ovarian wilms' cancer 10.1 MYC SMUG1
47 intestinal neuroendocrine benign tumor 10.1 ERBB2 KIT PGR
48 mediastinum sarcoma 10.1 KIT PGR TP53
49 bartholin's gland benign neoplasm 10.1 ESR1 PGR
50 endocrine organ benign neoplasm 10.1 KIT PGR TP53

Graphical network of the top 20 diseases related to Uterine Corpus Cancer:



Diseases related to Uterine Corpus Cancer

Symptoms & Phenotypes for Uterine Corpus Cancer

GenomeRNAi Phenotypes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.02 TP53 BRCA1 FBXW7 MYC PGR

MGI Mouse Phenotypes related to Uterine Corpus Cancer:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 KIT MYC PGR SMUG1 TP53 BRCA1
2 homeostasis/metabolism MP:0005376 10.24 BRCA1 ERBB2 ESR1 FBXW7 GATM KIT
3 endocrine/exocrine gland MP:0005379 10.22 BRCA1 ERBB2 ESR1 FBXW7 GATM KIT
4 behavior/neurological MP:0005386 10.21 TP53 BRCA1 ERBB2 ESR1 GATM KIT
5 cardiovascular system MP:0005385 10.21 FBXW7 KIT MYC PGR TP53 BRCA1
6 embryo MP:0005380 10.18 BRCA1 ERBB2 ESR1 FBXW7 KIT MYC
7 growth/size/body region MP:0005378 10.16 TP53 BRCA1 ERBB2 ESR1 FBXW7 GATM
8 integument MP:0010771 10.16 BRCA1 ERBB2 ESR1 FBXW7 GATM KIT
9 hematopoietic system MP:0005397 10.15 GATM KIT MYC PGR TP53 BRCA1
10 digestive/alimentary MP:0005381 10.13 BRCA1 ERBB2 ESR1 FBXW7 KIT MYC
11 immune system MP:0005387 10.13 BRCA1 ESR1 FBXW7 GATM KIT MYC
12 mortality/aging MP:0010768 10.11 BRCA1 ERBB2 ESR1 FBXW7 KIT MYC
13 neoplasm MP:0002006 10.06 KIT MYC PGR SMUG1 TP53 BRCA1
14 limbs/digits/tail MP:0005371 10.04 BRCA1 ERBB2 ESR1 KIT MYC PGR
15 muscle MP:0005369 10.03 BRCA1 ERBB2 ESR1 GATM KIT MYC
16 adipose tissue MP:0005375 10.02 BRCA1 ESR1 GATM MYC TP53
17 craniofacial MP:0005382 9.99 ERBB2 FBXW7 KIT MYC TP53
18 normal MP:0002873 9.97 MYC PGR TP53 BRCA1 ERBB2 ESR1
19 liver/biliary system MP:0005370 9.88 ESR1 GATM KIT MYC TP53
20 reproductive system MP:0005389 9.76 BRCA1 ERBB2 ESR1 GATM KIT MYC
21 renal/urinary system MP:0005367 9.65 BRCA1 ESR1 GATM KIT TP53
22 pigmentation MP:0001186 9.62 BRCA1 KIT MYC TP53
23 respiratory system MP:0005388 9.43 BRCA1 ERBB2 ESR1 FBXW7 KIT TP53
24 skeleton MP:0005390 9.23 BRCA1 ERBB2 ESR1 GATM KIT MYC

Drugs & Therapeutics for Uterine Corpus Cancer

Drugs for Uterine Corpus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 494)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 57-83-0 5994
2
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2 112809-51-5 3902
3
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
6
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
7
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
8
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
9
Ibuprofen Approved Phase 4 15687-27-1 3672
10
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
11
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
12
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
13
Zoledronic acid Approved Phase 4,Phase 3,Phase 1 118072-93-8 68740
14
Naproxen Approved, Vet_approved Phase 4,Phase 2 22204-53-1 1302 156391
15
Diphenhydramine Approved Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
16
Anastrozole Approved, Investigational Phase 4,Phase 1,Phase 2 120511-73-1 2187
17
Promethazine Approved Phase 4,Phase 2,Phase 1 60-87-7 4927
18
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
20
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
21 Progestins Phase 4,Phase 3,Phase 2,Phase 1
22 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
23 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
30 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
37 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
38 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
40 taxane Phase 4,Phase 3,Phase 1,Phase 2
41 Prednisolone acetate Phase 4,Phase 3,Phase 2
42 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
43 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
44 Neuroprotective Agents Phase 4,Phase 3,Phase 2
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2
47 Prednisolone phosphate Phase 4,Phase 3,Phase 2
48 Antiemetics Phase 4,Phase 3,Phase 2
49 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Early Phase 1
50 Methylprednisolone acetate Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 829)
id Name Status NCT ID Phase
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4
3 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4
4 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4
5 Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer Completed NCT00688909 Phase 4
6 A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis Completed NCT01382940 Phase 4
7 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4
8 Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion Completed NCT00160199 Phase 4
9 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4
10 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4
11 Difference of Gastric Microbiota in the Process of Correa's Model. Recruiting NCT02833363 Phase 4
12 A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer Terminated NCT00087620 Phase 4
13 Assessment and Tracking of Long-term Alefacept Safety Terminated NCT00454701 Phase 4
14 A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor Terminated NCT01283971 Phase 4
15 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3
16 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
17 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
18 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3
19 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
20 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Unknown status NCT00499616 Phase 3
21 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
22 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3
23 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed NCT01767155 Phase 3
24 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
25 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3
26 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
27 Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00003691 Phase 3
28 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3
29 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
30 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
31 Tachosil for the Prevention of Symptomatic Lymph Cysts Completed NCT01470677 Phase 3
32 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3
33 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
34 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3
35 Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women Completed NCT00490087 Phase 3
36 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
37 Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Completed NCT00003267 Phase 3
38 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
39 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3
40 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
41 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3
42 Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis Completed NCT00670319 Phase 3
43 Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3
44 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Completed NCT01012297 Phase 3
45 Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer Completed NCT00024427 Phase 3
46 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing TUR-BT Completed NCT00461591 Phase 3
47 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3
48 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. Completed NCT00056459 Phase 3
49 A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer Completed NCT00435409 Phase 3
50 Nutrition Intervention in Treating Women With Breast Cancer Completed NCT00002564 Phase 3

Search NIH Clinical Center for Uterine Corpus Cancer

Genetic Tests for Uterine Corpus Cancer

Anatomical Context for Uterine Corpus Cancer

MalaCards organs/tissues related to Uterine Corpus Cancer:

39
Lymph Node, Breast, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Corpus Cancer:

18
The Uterine Corpus

Publications for Uterine Corpus Cancer

Articles related to Uterine Corpus Cancer:

(show all 25)
id Title Authors Year
1
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. ( 27894165 )
2017
2
Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? ( 27261326 )
2016
3
A prediction model of survival for patients with bone metastasis from uterine corpus cancer. ( 27655906 )
2016
4
Genitofemoral neuropathy after pelvic lymphadenectomy in patients with uterine corpus cancer. ( 25486104 )
2015
5
Comorbidity is an independent prognostic factor in women with uterine corpus cancer: a nationwide cohort study. ( 24443826 )
2014
6
State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. ( 23125334 )
2013
7
Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. ( 21705925 )
2011
8
Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. ( 21508766 )
2011
9
Efficacy of para-aortic lymphadenectomy in early-stage endometrioid uterine corpus cancer. ( 21136177 )
2011
10
Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. ( 20142245 )
2010
11
Current status in the management of uterine corpus cancer in Korea. ( 20922137 )
2010
12
Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer. ( 20944170 )
2010
13
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. ( 20966700 )
2010
14
Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings. ( 19215544 )
2009
15
Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. ( 18201753 )
2008
16
Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. ( 18064567 )
2008
17
FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. ( 16710101 )
2006
18
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. ( 16198401 )
2005
19
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. ( 15581961 )
2004
20
Ethnic differences in uterine corpus cancer incidence and mortality in New Mexico's American Indians, hispanics and non-Hispanic whites. ( 9169158 )
1997
21
Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. ( 9441778 )
1997
22
Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. ( 7977518 )
1994
23
Estriol binding in uterine corpus cancer and in normal uterine tissues. ( 1869022 )
1991
24
Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway. ( 2384266 )
1990
25
A cohort analysis of breast cancer, uterine corpus cancer, and childbearing pattern in Norwegian women. ( 2273359 )
1990

Variations for Uterine Corpus Cancer

Copy number variations for Uterine Corpus Cancer from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 162862 22 22706138 22714284 Decreasing copy numb er GSTT1 Corpus uteri cancer

Expression for Uterine Corpus Cancer

Search GEO for disease gene expression data for Uterine Corpus Cancer.

Pathways for Uterine Corpus Cancer

Pathways related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 36)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 BRCA1 ERBB2 ESR1 KIT MYC PGR
2
Show member pathways
12.66 BRCA1 ESR1 MYC TP53
3 12.5 ERBB2 KIT MYC TP53
4 12.41 BRCA1 KIT MYC TP53
5
Show member pathways
12.37 BRCA1 ESR1 MYC SMUG1 TP53
6
Show member pathways
12.36 BRCA1 ERBB2 ESR1 KIT MYC PGR
7 12.34 BRCA1 ERBB2 MYC TP53
8
Show member pathways
12.18 ERBB2 KIT MYC TP53
9
Show member pathways
12.16 ERBB2 MYC TP53
10 12.1 ERBB2 ESR1 MYC TP53
11
Show member pathways
12.03 ERBB2 MYC TP53
12
Show member pathways
11.93 ERBB2 MYC TP53
13 11.89 BRCA1 ESR1 MYC TP53
14 11.84 ESR1 MYC TP53
15 11.83 ERBB2 MYC TP53
16
Show member pathways
11.8 BRCA1 ESR1 FBXW7 MYC PGR
17
Show member pathways
11.79 ERBB2 ESR1 PGR
18 11.6 ERBB2 MYC TP53
19 11.59 BRCA1 ERBB2 TP53
20
Show member pathways
11.59 ERBB2 ESR1 KIT MYC
21 11.5 BRCA1 ERBB2 MYC
22 11.39 BRCA1 MYC TP53
23 11.37 ERBB2 KIT MYC TP53
24 11.32 BRCA1 MYC TP53
25 11.28 BRCA1 MYC TP53
26 11.23 ESR1 MYC TP53
27 11.17 BRCA1 TP53
28 11.15 BRCA1 TP53
29 11.12 BRCA1 TP53
30 11.12 MYC TP53
31 11.1 ESR1 MYC
32 11.09 MYC TP53
33 10.98 MYC TP53
34
Show member pathways
10.97 MYC TP53
35 10.9 BRCA1 TP53
36 10.84 BRCA1 ERBB2 FBXW7 MYC TP53

GO Terms for Uterine Corpus Cancer

Cellular components related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.5 BRCA1 ESR1 FBXW7 MYC PGR SMUG1
2 protein complex GO:0043234 8.92 BRCA1 ESR1 MYC TP53

Biological processes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.85 BRCA1 ESR1 MYC PGR TP53
2 positive regulation of transcription, DNA-templated GO:0045893 9.81 BRCA1 ESR1 MYC TP53
3 cellular response to DNA damage stimulus GO:0006974 9.73 BRCA1 MYC SMUG1 TP53
4 negative regulation of gene expression GO:0010629 9.65 ESR1 MYC PGR
5 stem cell differentiation GO:0048863 9.54 ESR1 KIT
6 negative regulation of fibroblast proliferation GO:0048147 9.52 MYC TP53
7 phosphatidylinositol-mediated signaling GO:0048015 9.5 ERBB2 KIT TP53
8 positive regulation of cell cycle arrest GO:0071158 9.49 BRCA1 TP53
9 protein deubiquitination GO:0016579 9.46 BRCA1 ESR1 MYC TP53
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.4 BRCA1 TP53
11 cellular response to estrogen stimulus GO:0071391 9.37 ESR1 MYC
12 regulation of transcription from RNA polymerase II promoter GO:0006357 9.35 BRCA1 ERBB2 ESR1 KIT MYC
13 positive regulation of phospholipase C activity GO:0010863 9.26 ESR1 KIT
14 positive regulation of gene expression GO:0010628 9.02 BRCA1 ERBB2 KIT MYC TP53

Molecular functions related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.26 BRCA1 ESR1 PGR TP53
2 steroid binding GO:0005496 9.16 ESR1 PGR
3 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.62 ERBB2 KIT

Sources for Uterine Corpus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....